Evotec AG has entered into a multi-target drug discovery collaboration with UCB in the field of immunology. Evotec will apply its drug discovery expertise to identify small molecules against a selected number of targets, then optimize a preclinical candidate. Evotec will receive research funding and will receive early stage discovery, preclinical and clinical milestones, as well as royalties on sales of any approved drugs from the collaboration. Financial details were not disclosed.   Dr. Werner...